- Home
- PAX vs IMCR Comparison
PAX vs IMCR Comparison
Compare PAX & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAX
- IMCR
- Stock Information
- Founded
- PAX 1988
- IMCR 2008
- Country
- PAX Cayman Islands
- IMCR United Kingdom
- Employees
- PAX N/A
- IMCR N/A
- Industry
- PAX Investment Managers
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAX Finance
- IMCR Health Care
- Exchange
- PAX Nasdaq
- IMCR Nasdaq
- Market Cap
- PAX 2.3B
- IMCR 1.8B
- IPO Year
- PAX 2021
- IMCR 2021
- Fundamental
- Price
- PAX $14.96
- IMCR $33.42
- Analyst Decision
- PAX Strong Buy
- IMCR Buy
- Analyst Count
- PAX 1
- IMCR 8
- Target Price
- PAX $14.00
- IMCR $57.00
- AVG Volume (30 Days)
- PAX 557.1K
- IMCR 288.3K
- Earning Date
- PAX 11-04-2025
- IMCR 11-05-2025
- Dividend Yield
- PAX 5.84%
- IMCR N/A
- EPS Growth
- PAX N/A
- IMCR N/A
- EPS
- PAX 0.53
- IMCR N/A
- Revenue
- PAX $397,504,000.00
- IMCR $356,145,000.00
- Revenue This Year
- PAX N/A
- IMCR $29.67
- Revenue Next Year
- PAX $21.28
- IMCR $11.12
- P/E Ratio
- PAX $28.34
- IMCR N/A
- Revenue Growth
- PAX 26.52
- IMCR 26.78
- 52 Week Low
- PAX $9.43
- IMCR $23.15
- 52 Week High
- PAX $15.09
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- PAX 75.56
- IMCR 44.20
- Support Level
- PAX $13.29
- IMCR $35.33
- Resistance Level
- PAX $14.58
- IMCR $36.76
- Average True Range (ATR)
- PAX 0.30
- IMCR 1.46
- MACD
- PAX 0.14
- IMCR -0.12
- Stochastic Oscillator
- PAX 91.26
- IMCR 24.65
About PAX Patria Investments Limited
Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.